On April 13, 2023 Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, reported that it will premiere data from its early lung cancer detection discovery platform, the Nucleix EpiCheck Lung Atlas, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Event in Orlando, April 14-19 (Press release, Nucleix, APR 13, 2023, View Source [SID1234630068]). The proprietary Lung Atlas was constructed and developed as part of a multi-institutional effort to map epigenetic and genomic changes associated with early-stage lung cancer, particularly stage I disease.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentations at AACR (Free AACR Whitepaper) include:
Development of a Genome-Wide Multiomic Atlas of Early-Stage Lung Cancer Enables Identification of Novel Methylation Biomarkers for Disease Detection Beyond TCGA
Session date and time: April 17 at 1:30pm ET
Machine-Learning-Based Epigenetic Detection of Early-Stage Lung Cancers Using the EpiCheck Liquid Biopsy Platform
Session date and time: April 18 at 1:30pm ET
"When lung cancer is detected early, it is more likely that patients will survive the disease," said Chris Hibberd, CEO, Nucleix. "Currently though, most patients are diagnosed with late-stage cancer, even though research has shown that five-year survival rates are up to 10 times greater when lung cancer is detected early.i Results demonstrate the strength of Nucleix’s Lung EpiCheck assay and our differentiated approach for the discovery and identification of novel biomarkers for non-invasive lung cancer screening. We are leveraging these findings to advance a new generation of Lung EpiCheck, which incorporates novel markers from the Lung Atlas and is optimized to detect minute cancer epigenetic signals with greater sensitivity. The next step is well underway as we evaluate the new assay in the Sightline Trial, a 5,000 patient multicenter study in high-risk current and former smokers."
Currently there are limited options for early lung cancer detection and only 10% of the nearly 15 million high-risk smokers recommended to receive low-dose CT imaging adhere to current guidelines.ii The Lung Atlas will aid in Nucleix’s development of the next generation of clinical assays. Nucleix’s Lung EpiCheck analyzes changes in multiple methylation markers to screen for lung cancer using a non-invasive blood sample, with a focus on testing individuals who are at high-risk based on smoking history. Lung EpiCheck has been optimized to focus on sensitivity, so that physicians have a better chance of early detection and patients have a better chance of successful treatment.
Learn more about Nucleix’s Lung EpiCheck.